<DOC>
	<DOCNO>NCT02217488</DOCNO>
	<brief_summary>This clinical trial investigate safety , tolerability pharmacokinetic profile DG3173 double-blind , randomize , placebo-controlled , single dose escalation Phase 1 study involve 72 healthy volunteer . Individuals receive 2000 µg DG3173 via single dose subcutaneous injection .</brief_summary>
	<brief_title>Single Ascending Dose Tolerability Study DG3173</brief_title>
	<detailed_description />
	<criteria>Ethnic origine : Caucasian Weight : 5595 kg BMI : 1929 kg/qm Medical history without clinically relevant pathology Physical examination parameter lung function without sign clinically relevant pathology Electrocardiogram record without sign clinically relevant pathology , particular QTc ( Bazett ) &lt; 440ms Values hematology , biochemistry coagulation test blood urine within normal range show clinically relevant deviation judge medical investigator ( particular normal value ALAT , ASAT , LDH , gammaGT , alkaline phosphatase , alphaamylase bilirubin ) Having give write informed consent studyrelated activity carry Evidence clinically relevant pathology disease Any history moderate severe hypertension , hypotension orthostatic hypotension Mental handicap Legal incapacity Any history clinically important emotional and/or psychiatric illness clinically important neurological disorder and/or epilepsy Chronic diarrhea chronic gastrointestinal disorder Acute chronic gastroduodenal ulcer Presence history endocrine disorder Presence history gall stone disease , presence exclude mean upper abdominal ultrasound Known hypersensitivity study drug constituent study drug History relevant allergy , especially drug and/or food allergy Strict vegetarian Regular treatment medication three month prior randomization Receipt prescription nonprescription medication , include multivitamin preparation within 14 day prior drug administration duration study Use St. John´s Wort Ginkgo Biloba ( also know Ginkgo Bilbao ) within 48 hour prior randomization Participation clinical study within 30 day prior randomization Donation blood within 60 day prior randomization History use tobacco nicotinecontaining product within past three month Any history alcohol abuse drug addiction Positive result screen drug abuse ( cocaine , amphetamine/methamphetamine , tetrahydrocannbinol , opiates ) alcohol ( breath test ) screen admission Positive screen result HBsAg , antiHCV , antiHIV1 &amp; 2 Consumption abnormal quantity coffee tea ( i.e . 5 cup per day [ 1 cup = 150 ml ] Any disease Investigator´s opinion would exclude subject study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>